Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06892002 · ClinicalTrials.gov registry record
Description of Patients With Type 1 Diabetes Treated With Teplizumab
A clinical trial, sponsored by Sanofi.
- Completed
- Registry status
- 110
- Enrollment target
NCT06892002 is a clinical trial that has completed, run by Sanofi. The registered enrollment target is 110 participants.
The verdict
NCT06892002 has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
Study Summary
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus presence of islet autoantibodies, without the presence of dysglycemia and symptoms. Stage 2 T1D includes the presence of islet autoantibodies and dysglycemia, also with no symptoms. Stage 3 T1D includes presence of islet autoantibodies, overt hyperglycemia, and symptoms; most patients with Stage 3 T1D meet standard diagnostic criteria for diabetes and require insulin treatment. Teplizumab has been shown to delay progression to Stage 3 in participants at Stage 2 in a Phase 2 clinical trial, leading to subsequent approval in the United States of America (USA). Patients outside of the USA are able to receive the treatment through Pre-Registration Import Licenses and Managed Access Programs. The current study will collect data on the use of teplizumab in routine care, to better understand which patients received teplizumab and how these patients were managed after they received the treatment.
Interventions
- DRUG Teplizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-02-11 |
| Est. Completion | 2025-08-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06892002
The ClinicalTrials.gov registry entry for NCT06892002 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Teplizumab is the first listed.
NCT06892002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06892002 about?
NCT06892002 is a clinical study titled "Description of Patients With Type 1 Diabetes Treated With Teplizumab". Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus presence of islet autoantibodies, without the presence of dysglycemia ...
What is the current status of trial NCT06892002?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2025-02-11. Estimated completion is 2025-08-05.
What interventions are being tested in trial NCT06892002?
The interventions under investigation include: Teplizumab (DRUG).
Who is sponsoring clinical trial NCT06892002?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.